BPC-157 dosage: what has actually been published
Published figures for the four routes HHS’s 2026 policy lists. Almost all of them are animal doses.
There is no established human dose of BPC-157. Published doses come almost entirely from rat studies and are stated per kilogram of body weight, which does not convert reliably to people. Published protocols vary; a licensed provider sets your dose; never self-dose. Below are the published figures for the four routes the 2026 policy lists.
BPC-157 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer BPC-157.
Published BPC-157 doses by route
| Route | Human dose | Published animal study doses | Source |
|---|---|---|---|
| Subcutaneous injection | No established human dose; no published human study by this route found | No subcutaneous dose study found. Rat studies mostly inject into the abdominal cavity (intraperitoneal): 10 µg/kg or 10 ng/kg once daily, a route not used in people | Cerovecki et al. 2010; Japjec et al. 2021 |
| Intramuscular injection | No established human dose | A pharmacokinetic study, not a dosing study: rats 20–500 µg/kg, dogs 6–150 µg/kg; half-life under 30 minutes | He et al. 2022 |
| Oral | No established human dose; a registered phase 1 trial of 1 mg oral tablets has no posted results | Rats: 0.16 µg/mL in drinking water (about 12 mL per rat per day) | Cerovecki et al. 2010; Japjec et al. 2021; NCT02637284 |
| Topical | No established human dose | Rats: a cream with 1.0 µg BPC-157 per gram, applied as a thin layer over the injury site | Cerovecki et al. 2010 |
This table reports what studies used. It is not a dosing recommendation, and animal doses must not be scaled to a human dose.
Published protocols vary; a licensed provider sets your dose
Published protocols vary; a licensed provider sets your dose; never self-dose. Doses posted on vendor sites, forums and “dosage charts” do not come from human trials, because there are no completed human dose-finding trials of BPC-157 to draw on.
A prescriber who decides BPC-157 is appropriate writes the dose, route and schedule on a patient-specific prescription, and the 503A pharmacy labels the product to match. Follow that label, not a chart.
Why published BPC-157 dosage charts differ
- They convert per-kilogram rat doses to human doses with different formulas, none validated in people.
- They mix routes: most rat studies used intraperitoneal injection, which is not how people are dosed.
- They assume vials hold what the label says. Research-use vials have no patient-specific label and no pharmacy answerable for content.
- Some charts combine BPC-157 with other peptides. The 2026 policy covers one active ingredient per product, so combined dosing has no place in a compounded prescription.
- Rat studies usually tested a single dose level, so dose-response is unknown.
Reconstitution basics for injectable BPC-157
If a provider prescribes an injectable form, the pharmacy label and the prescriber’s instructions govern everything: whether it arrives as a solution or a powder, what to mix it with, how much, and how to store it. General sterile-technique basics:
- Wash your hands and clean the vial stopper with an alcohol swab before every use.
- Use a new sterile syringe for every injection; never reuse or share one. Under the policy, the one device packaged with the drug is an FDA 510(k)-cleared syringe.
- Mix and store exactly as the pharmacy label says, and discard by the date on the label.
- Do not use the product if it looks cloudy, discolored or has particles, and call the pharmacy.
- Never combine it with another product in the same syringe or vial.
How much BPC-157 should I take per day?
No human study has established a daily dose of BPC-157. Published figures are rat doses per kilogram of body weight, such as 10 µg/kg, and they cannot be converted into a human dose reliably. Published protocols vary; a licensed provider sets your dose; never self-dose, and never dose from a research-use vial.
Is oral BPC-157 dosed differently from injections?
Nobody knows for people. Rat studies gave oral BPC-157 in drinking water and injected doses by body weight, and no published human study compares the two. Under the 2026 policy, an oral product also needs documentation that it is adequately bioavailable in humans. A licensed provider sets any dose.
Sources
- Cerovecki et al., J Orthop Res 2010 — Pentadecapeptide BPC 157 (PL 14736) in a rat medial collateral ligament model (read November 2, 2026)
- Japjec et al., Biomedicines 2021 — Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats (read November 2, 2026)
- He et al., Front Pharmacol 2022 — Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs (read November 2, 2026)
- ClinicalTrials.gov — NCT02637284, PCO-02 (BPC-157 oral tablets) Phase I safety and pharmacokinetics trial, status unknown (read November 2, 2026)
- Józwiak et al., Pharmaceuticals 2025 — Reply to Sikiric et al., comment on “Multifunctionality and Possible Medical Application of the BPC 157 Peptide” (read November 2, 2026)
- Vasireddi et al., HSS Journal 2025 — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (read November 2, 2026)
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026) (read November 2, 2026)
- Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Nutritional Outlook (Bigica), Nov 2 2026 — HHS peptide compounding policy: supplement industry implications (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·